Financial Performance - The company reported a net profit of 1.793 billion yuan for 2024, representing a year-on-year increase of 11.99% compared to 1.601 billion yuan in 2023 [1] - Revenue for 2024 reached 12.276 billion yuan, up 6.4% from 11.538 billion yuan in 2023 [1] - Basic earnings per share increased to 1.0133 yuan, a rise of 12.18% from 0.9033 yuan in the previous year [1] - The return on equity (ROE) slightly decreased to 13.70% from 13.91% in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 99.14136 million shares, accounting for 57.62% of the circulating shares, with a decrease of 2.17455 million shares compared to the previous period [2] - HKSCC NOMINEES LIMITED remains the largest shareholder with 30.15020 million shares, representing 17.52% of the total share capital [3] - Shenzhen Xinchongkang Investment Partnership holds 26.08280 million shares, making up 15.16% of the total [3] Dividend Distribution - The company announced a dividend distribution of 0.2 yuan per share (including tax) [4]

Financial Performance - For the year ended December 31, 2024, total revenue reached RMB 12,275.8 million, an increase of approximately RMB 737.8 million or 6.4% compared to the previous year[3] - The profit attributable to equity holders of the parent company was approximately RMB 1,793.4 million, representing a growth of 12.0% from RMB 1,601.1 million in 2023[3] - The net cash flow from operating activities was approximately RMB 2,576.7 million, a decrease of about 6.4% compared to RMB 2,753.5 million in the prior year[3] - The gross profit for the year was RMB 4,149.3 million, reflecting a slight increase of 1.3% from RMB 4,094.8 million in 2023[5] - The group reported a pre-tax profit of RMB 2,091,263 thousand for the year ended December 31, 2024, compared to RMB 1,837,887 thousand in 2023, reflecting an increase of approximately 13.8%[17] - Total revenue for the year ended December 31, 2024, was RMB 12,275,775 thousand, an increase from RMB 11,537,996 thousand in 2023, representing a growth of approximately 6.4%[21] Dividends and Earnings - The board proposed a final dividend of RMB 2.0 per share, amounting to a total of approximately RMB 354.2 million[3] - The proposed final dividend for the year ending December 31, 2024, is RMB 2.0 per 10 shares, totaling approximately RMB 354,186,000 (tax included)[34] - The basic earnings per share for the year ending December 31, 2024, is RMB 1.014, compared to RMB 0.903 for 2023, reflecting an increase of approximately 12.3%[37] Assets and Liabilities - Total non-current assets increased to RMB 16,319.2 million from RMB 15,602.3 million in 2023[8] - Current assets decreased to RMB 7,608.2 million from RMB 10,874.4 million in the previous year[8] - Total liabilities decreased from RMB 9,584.2 million in 2023 to RMB 5,480.5 million in 2024[9] - The total equity attributable to equity holders of the parent company increased to RMB 13,619.3 million from RMB 12,556.8 million in the previous year[9] Revenue Breakdown - The revenue breakdown by region for 2024 shows North America at RMB 7,852,729 thousand, Europe at RMB 2,271,934 thousand, and mainland China at RMB 1,847,332 thousand[18] - The laboratory services segment generated revenue of RMB 7,046,875 thousand, while the CMC services segment contributed RMB 2,988,773 thousand, indicating strong performance across these divisions[17] - Total revenue from the European market increased significantly from RMB 1,844,397 thousand in 2023 to RMB 2,271,934 thousand in 2024, marking a growth of approximately 23.2%[18] - Laboratory services revenue grew to RMB 7,046,875 thousand in 2024, up 5.8% from RMB 6,660,117 thousand in 2023[21] Research and Development - Research and development costs amounted to RMB 469.3 million, up from RMB 448.3 million in the previous year[5] - The company operates 21 R&D centers and production bases across China, the UK, and the US, enhancing its global drug development services[44] - The company has established a bioanalytical platform in China and the US to support global clinical trials for small molecules and biologics[50] - The company is currently managing 1,062 ongoing clinical trial projects, including 94 Phase III trials and 407 Phase I/II trials[67] Operational Efficiency and Technology - The company emphasizes enhancing operational efficiency and service capabilities to meet market demands[44] - The company has begun applying artificial intelligence tools in laboratory chemistry and plans to continue expanding investments in AI and automation to enhance research efficiency[61] - The company is actively exploring the application of AI and machine learning in process chemistry research and production optimization to improve CDMO service efficiency[64] - The company achieved significant progress in digitalization and intelligence within its clinical sector, integrating multiple AI applications across various business areas[68] Market Outlook and Strategy - The company aims to become a global leader in multi-therapy drug development services, focusing on small molecules, large molecules, and cell and gene therapies[44] - The company plans to enhance its large molecule drug discovery and CDMO service capabilities in 2025, establishing a quality system that adheres to the highest international regulatory standards[144] - The company aims to strengthen its cell and gene therapy service platform by leveraging synergies between its U.S. and U.K. operations, gradually expanding its customer base and operational efficiency[145] - The company recognizes the risk of declining demand in the drug development service market due to fluctuations in investment and budget changes from multinational pharmaceutical companies[149] Employee and Talent Management - The company has a total of 21,370 employees as of December 31, 2024, compared to 20,295 employees as of December 31, 2023, indicating a growth of approximately 5.3% in workforce[159] - The company is committed to attracting and retaining top talent to maintain its competitive edge in providing high-quality services[149] - The company will optimize its human resources management system to enhance talent attraction, assessment, training, and motivation mechanisms[150] Compliance and Risk Management - The company has established an audit committee consisting of three independent non-executive directors, ensuring compliance with applicable accounting principles and standards[176] - The company is actively monitoring changes in pharmaceutical policies and is committed to meeting regulatory requirements to avoid operational disruptions[152] - The company faces risks from international policy changes and trade tensions, which could adversely affect its operations in overseas markets[153] Shareholder Actions - The company repurchased a total of 9,608,288 A-shares at a total cost of approximately RMB 200.1 million during the reporting period, with all shares canceled by December 25, 2024[160] - The company repurchased 7,263,300 H-shares at a total cost of approximately HKD 99.8 million from December 2024 to January 2025, which are held as treasury shares[162] - The company conducted a series of repurchases and redemptions of convertible bonds totaling approximately USD 573.1 million during the reporting period[166] Strategic Partnerships and Acquisitions - The company signed a strategic cooperation agreement with AstraZeneca Investment (China) for integrated services in drug discovery and development, increasing its investment in the AstraZeneca fund to RMB 191 million, representing 8.46% of the total subscription[120] - The company completed the acquisition of approximately 78.5% of Shanghai Jiying Intelligent Technology Co., Ltd. and a controlling transaction with Zhejiang Haixin Zhihui Technology Co., Ltd. in February 2025[68] - The company plans to acquire a 51.39% stake in Hai Xin Zhi Hui for approximately RMB 185.0 million, expected to complete by February 2025, enhancing its capabilities in digital tumor patient management[172]

Investment Rating - The investment rating for WuXi AppTec (603259) is "Outperform the Market" and is maintained [2][13]. Core Insights - In 2024, WuXi AppTec reported a revenue of 39.24 billion yuan, a year-on-year decrease of 2.7%. Excluding COVID-19 commercialization projects, revenue increased by 5.2%. The net profit attributable to shareholders was 9.45 billion yuan, down 1.6% year-on-year, while the adjusted net profit was 10.58 billion yuan, a decrease of 2.5% year-on-year, with an adjusted net profit margin of 27.0%, reaching a historical high [6][13]. - The fourth quarter of 2024 saw a revenue of 11.54 billion yuan, a year-on-year increase of 6.9%, and an adjusted net profit of 3.24 billion yuan, up 20.4% year-on-year [6][13]. Business Segment Performance Chemical Business - Revenue reached 29.05 billion yuan, with an 11.2% year-on-year increase when excluding specific commercialization projects. The small molecule D&M business generated 17.87 billion yuan, with a 6.4% year-on-year increase [6][10]. - The TIDES business (oligonucleotides and peptides) experienced rapid growth, with revenue of 5.80 billion yuan, a 70.1% increase year-on-year, and a backlog of orders growing by 103.9% [6][10]. Testing Business - Revenue was 5.67 billion yuan, down 4.8%. Laboratory analysis and testing services generated 3.86 billion yuan, reflecting an 8.0% year-on-year decline [7][10]. Biological Business - Revenue was 2.54 billion yuan, remaining stable year-on-year. Non-tumor business revenue grew by 29.9% [10][11]. Financial Data and Forecast - For 2024, the total revenue is projected at 39.24 billion yuan, with a forecasted increase to 43.58 billion yuan in 2025, representing an 11.1% year-on-year growth [8][11]. - The net profit for 2024 is expected to be 9.45 billion yuan, increasing to 11.27 billion yuan in 2025, reflecting a 19.2% year-on-year growth [8][11]. Customer and Order Growth - By the end of 2024, the company had approximately 6,000 active customers, with a backlog of orders amounting to 49.31 billion yuan, a 47.0% year-on-year increase [13].

Investment Rating - The report maintains a rating of "Accumulate" for WuXi AppTec (603259) with a target price of 93.84 CNY, up from the previous forecast of 71.82 CNY [1][11]. Core Views - The report highlights strong growth in backlog orders and a significant increase in peptide business, indicating a positive long-term growth outlook for the company [1][11]. - The company is expected to achieve a revenue of 39.24 billion CNY in 2024, reflecting a decrease of 2.7% year-on-year, while the net profit attributable to the parent company is projected at 9.45 billion CNY, down 1.6% [2][11]. - The report notes that the fourth quarter of 2024 is expected to show a revenue of 11.54 billion CNY, representing a 6.9% increase, with an adjusted net profit of 3.234 billion CNY, up 20.3% [11]. Financial Summary - Revenue and Profit Forecasts: - 2023A: Revenue 40.34 billion CNY, Net Profit 9.607 billion CNY - 2024A: Revenue 39.241 billion CNY, Net Profit 9.450 billion CNY - 2025E: Revenue 42.602 billion CNY, Net Profit 11.778 billion CNY - 2026E: Revenue 47.327 billion CNY, Net Profit 12.846 billion CNY - 2027E: Revenue 52.801 billion CNY, Net Profit 14.749 billion CNY [2][13]. - Earnings Per Share (EPS) Forecasts: - 2023A: 3.33 CNY - 2024A: 3.27 CNY - 2025E: 4.08 CNY - 2026E: 4.45 CNY - 2027E: 5.11 CNY [2][13]. - Return on Equity (ROE) Forecasts: - 2023A: 17.4% - 2024A: 16.1% - 2025E: 17.5% - 2026E: 16.8% - 2027E: 17.0% [2][13]. Market Data - The stock has a 52-week price range of 36.87 to 69.68 CNY, with a total market capitalization of 201.235 billion CNY [3][11]. - The company has a net asset value per share of 20.30 CNY and a price-to-book ratio of 3.4 [4][11]. Business Performance - The report indicates that the chemical business is expected to grow by 11.2% in 2024, excluding the impact of COVID-19 commercialization orders, with an adjusted gross margin of 46.4% [11]. - The peptide business (TIDES) is projected to achieve a revenue of 5.8 billion CNY in 2024, marking a 70.1% increase, with backlog orders growing by 103.9% [11].

Investment Rating - The investment rating for WuXi AppTec is maintained as "Buy" for both A and H shares [6][7]. Core Views - The company reported a revenue of 39.24 billion RMB for 2024, a decrease of 2.7% year-on-year, but a growth of 5.2% year-on-year when excluding COVID-19 impacts, which aligns with expectations [1]. - The net profit attributable to shareholders for 2024 was 9.45 billion RMB, down 1.6% year-on-year, while the adjusted non-IFRS net profit was 10.58 billion RMB, a decrease of 2.5% year-on-year [1]. - The company has seen a significant increase in its order backlog, with expectations for accelerated growth in 2025-2026, leading to a positive outlook [1][2]. Summary by Sections Financial Performance - In Q4 2024, revenue increased by 6.9% year-on-year, and net profit attributable to shareholders surged by 90.6% year-on-year, driven by improved operational efficiency and favorable exchange rate fluctuations [1]. - The company’s gross margin improved to 43.5% in Q4 2024 from 40.9% in Q4 2023 [1]. Order Backlog and Growth Prospects - As of the end of 2024, the order backlog reached 49.31 billion RMB, reflecting a year-on-year growth of 47.0% [2]. - The TIDES segment showed remarkable growth, with order backlog increasing by 104% year-on-year [2]. Segment Performance - WuXi Chemistry reported a revenue of 29.05 billion RMB in 2024, a slight decrease of 0.4% year-on-year, but a growth of 11.2% year-on-year when excluding COVID-19 impacts [3]. - The CDMO segment generated 17.87 billion RMB, with a year-on-year growth of 6.4% when excluding COVID-19 impacts [3]. Profitability Forecast - The forecast for net profit attributable to shareholders for 2025-2027 is 11.79 billion RMB, 13.56 billion RMB, and 16.74 billion RMB, representing year-on-year growth rates of 24.8%, 14.95%, and 23.5% respectively [5]. - The company’s target prices are set at 89.42 RMB for A shares and 100.99 HKD for H shares, based on a sum-of-the-parts valuation [5][6]. Valuation - The company is valued at 258.24 billion RMB for A shares and 291.66 billion HKD for H shares, reflecting adjustments due to changes in the DDSU segment [11].

Core Viewpoint - The Hong Kong stock market showed strong performance, with the Hang Seng Index rising 2.46% to a three-year high, driven by robust earnings in technology stocks, signs of economic stabilization, and positive policy expectations [1] Group 1: Market Performance - The Hang Seng Index closed at 24,740.57 points, up 595 points, with a total trading volume of 285.935 billion HKD [1] - The Hang Seng Tech Index increased by 3.96%, closing at 6,105.5 points, while the Hang Seng China Enterprises Index rose by 2.79% to 9,177.8 points [1] Group 2: Blue-Chip Stocks - Baidu Group-SW led blue-chip stocks with a 12.22% increase, closing at 103.3 HKD, contributing 15.93 points to the Hang Seng Index [2] - WuXi AppTec (药明康德) rose by 10.54% to 72.35 HKD, contributing 4.07 points to the index [2] - Other notable performers included Li Auto-W, which increased by 6.76%, and China Longjian Infrastructure, which fell by 2.93% [2] Group 3: Sector Highlights - Large technology stocks performed well, with Baidu up 12%, Alibaba and JD both rising over 5% [3] - AI concept stocks saw strong gains, with Baidu Group-SW up 12.22%, Kingsoft Cloud up 10.86%, and Alibaba-W up 5.83% [3] - The CRO sector also performed well, with WuXi AppTec up 10.54% and other CRO stocks showing significant increases [5] Group 4: Gold Stocks - Gold stocks collectively rose as international gold prices reached new highs, with Lingbao Gold up 7.3% and Shandong Gold up 6.99% [7] - UBS forecasts gold prices could reach 3,200 USD per ounce in the next four quarters, with Macquarie analysts predicting a potential peak of 3,500 USD per ounce by Q3 [7] Group 5: Robotics Sector - The robotics sector saw significant gains, with Yujian Technology up 27.88% after launching a humanoid robot [8] - Midea Group also reported advancements in humanoid robot development, indicating a push towards commercialization [8] Group 6: Notable Stock Movements - CanSino Biologics surged 25.26% after receiving breakthrough therapy designation for a new drug [9] - Hillstone Networks reported a 28.89% increase in revenue, with a 240.67% rise in net profit [10] - NIO-SW rose 8.95% following a strategic partnership with CATL to enhance battery swap services [11]

Investment Rating - The report initiates coverage with a "Buy" rating for WuXi XDC [1][3][4] Core Insights - The global ADC CRDMO market is expanding, with the company benefiting from a growing order pipeline and a dual-factory strategy that enhances capacity and customer retention. The company is also entering the XDC market to create a second growth curve [3][4][5] Summary by Sections Company Overview - WuXi XDC is a leading end-to-end ADC CRDMO provider, benefiting from high industry demand and a growing order book. The projected EPS for 2024-2026 is 0.89, 1.24, and 1.66 CNY respectively, with a target price of 43.4 CNY based on a 35X PE for 2025 [4][16] Market Dynamics - The global ADC drug market is expected to grow to 64.7 billion USD by 2030, with a CAGR of 30% from 2022 to 2030. The outsourcing market for ADC and broader bioconjugates is projected to reach 11 billion USD by 2030, with a CAGR of 28% [4][40] Financial Performance - The company has shown strong revenue growth, with revenues increasing from 311 million CNY in 2021 to an estimated 2.124 billion CNY in 2023, representing a CAGR of 180.7%. The net profit is expected to grow significantly, reaching 1.067 billion CNY in 2024 [8][31] Production Capacity and Strategy - The company is implementing a dual-factory strategy to enhance global production capacity, with new facilities in Singapore expected to be operational by the end of 2025. The company has 18 clinical stage III projects and is advancing its ADC pipeline [5][19][37] Growth Opportunities - The XDC market is emerging, with significant potential in non-oncological indications. The company is strategically positioned to capitalize on this growth by leveraging its existing technology and expanding its project and client base [5][21][22]

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding the CSI 300 Index by more than 5% over the next six months [9]. Core Insights - The pharmaceutical sector experienced a decline of 0.96% on March 7, 2025, underperforming the CSI 300 Index by 0.65 percentage points, ranking 22nd among 31 sub-industries [4]. - The approval of ARS's Neffy (1 mg epinephrine nasal spray) by the FDA marks a significant innovation in the delivery method for treating type I allergic reactions in children aged 4 and above, representing the first major advancement in 35 years for this patient group [5][9]. - Notable stock performances included Aosaikang (+9.99%), Yipinhong (+9.77%), and Rejing Biology (+8.84%) on the gainers' list, while Aopumai (-6.26%), Puri Eye (-5.97%), and BGI (-4.86%) led the decliners [4]. Summary by Sections Market Performance - As of March 7, 2025, the pharmaceutical sector's performance was -0.96%, with sub-sectors like in vitro diagnostics (-0.43%) and blood products (-0.72%) performing better, while hospitals (-2.11%) and medical devices (-1.67%) lagged [4]. Industry News - The FDA's approval of Neffy is a pivotal development for the treatment of severe allergic reactions in children, highlighting the ongoing innovation in the pharmaceutical industry [5]. - Companies such as Jingxin Pharmaceutical announced an increase in their share repurchase plan, raising the total amount from a minimum of 200 million RMB to 350 million RMB [5]. - Nouvegen and BGI have entered a strategic cooperation agreement to leverage their respective expertise in reproductive genetics, tumor prevention, chronic disease management, and infection control [5]. Company News - Heng Rui Pharmaceutical received approval for clinical trials of several new drugs, indicating ongoing research and development efforts [6]. - Kanglong Chemical reported the completion of a share reduction plan, with a total of 10,666,716 shares reduced, representing 0.60% of the company's total share capital [6].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical industry, indicating that the industry is expected to outperform the benchmark index over the next 12 months [33]. Core Insights - The pharmaceutical sector is experiencing a recovery, with significant growth in sub-sectors such as internet healthcare, biotechnology, and medical devices, which saw increases of 36%, 34%, and 24% respectively in February 2025 [3][6]. - The report highlights the government's encouragement of innovative drug development, including discussions on expanding payment channels for innovative drugs and the potential establishment of a category for innovative drugs in the insurance framework [4][24]. - The medical device market is showing signs of recovery, with the domestic medical imaging equipment market growing over 47% year-on-year in January 2025, and an increase in the number of CT devices awarded contracts by 4.2% compared to the previous year [4][30]. Market Review - In February 2025, the Hang Seng Composite Industry Index rose by 12.8%, while the Hang Seng Healthcare Index increased by 16.3%, outperforming the market by 3.5 percentage points [3][6]. - The A-share market saw the Shanghai and Shenzhen 300 Index decline by 3% in January, with the pharmaceutical and biotechnology index dropping by 3.8%, but rebounding in February with a 5.1% increase [14]. - The report notes that all 13 sub-sectors in the pharmaceutical industry experienced declines in January, but several sub-sectors, including hospitals and medical devices, showed significant gains in February [14]. Industry Data Update - The report indicates that the basic medical insurance revenue for January 2025 reached 314.3 billion yuan, a year-on-year increase of 10.4%, with expenditures growing by 8.5% [17]. - The commercial health insurance sector is also expanding, with original premium income reaching 977.3 billion yuan in 2024, reflecting an 8.2% year-on-year growth [20]. - Medical device exports, particularly for ECG recorders, ultrasound diagnostic devices, and CT machines, have accelerated in both quantity and value since the second half of 2024 [21]. Industry News Summary - The National Healthcare Security Administration held a meeting to support innovative drug development, engaging with major pharmaceutical companies to discuss strategies for enhancing the market for innovative drugs [23][24]. - A draft opinion on improving the drug pricing mechanism has circulated, proposing measures to support innovative drug development and enhance drug accessibility [28]. - The report mentions ongoing efforts to regulate prices in the healthcare sector, including a comprehensive governance initiative for central venous catheter pricing, which has led to significant price reductions for related medical services [29][30].

Market Review - The overall market sentiment for the pharmaceutical sector remains cautious, with the CITIC Pharmaceutical Index declining by 2.78%, underperforming the CSI 300 Index by 0.56 percentage points, ranking 21st among 30 primary industries [4] - The top ten stocks by growth this week include Nuo Cheng Jian Hua-U, Chang Yao Holding, and Shanghai Yi Zhong, with growth rates of 20.98%, 20.96%, and 18.78% respectively [3][4] - Conversely, the bottom ten stocks include Jiangsu Wu Zhong and Xin Gan Jiang, with declines of 4% and 6% respectively [4] Industry and Stock Events - The pharmaceutical sector's valuation is currently low, with public funds (excluding pharmaceutical funds) also underweight in this sector. The outlook for the pharmaceutical industry in 2025 remains optimistic due to macroeconomic factors such as the recovery of US Treasury yields and the driving effect of large categories and products [7] - In the innovative drug segment, there is a shift from quantity logic to quality logic, emphasizing the importance of product differentiation and internationalization. Companies to watch include Heng Rui, Bai Ji, and Nuo Cheng Jian Hua [7] - The medical device sector is expected to benefit from the acceleration of equipment renewal policies, with key companies like Mai Rui Medical and Xin Hua Medical positioned to gain from increased orders [7] - The IVD market is anticipated to return to high growth, with a focus on companies like An Tu Biology and Di Rui Medical, as domestic market penetration continues to expand [7] - The blood products sector is set for growth, with a favorable regulatory environment for plasma collection and increasing demand post-pandemic. Companies such as Tian Tan Biology and Bo Ya Biology are recommended [12] Antibiotics Industry Update - The global antibiotic market is projected to grow steadily, with a market size of approximately 98 billion yuan in China from 2017 to the third quarter of 2024. The top three hospital antibiotics in 2024 are expected to be injectable formulations of Piperacillin and Tazobactam, with sales of 4.94 billion yuan [15][16] - The production capacity for key antibiotic intermediates is under strict regulatory control, with the latest guidelines from the National Development and Reform Commission continuing to restrict new capacity in antibiotic intermediates [17] - The price trends for key antibiotic products such as Penicillin and 6-APA have shown fluctuations, with 6-APA's price reaching 320 yuan per kilogram by January 2025 [24][25]